603087 甘李药业
已收盘 01-13 15:00:00
资讯
新帖
简况
甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%
证券之星 · 01-13 22:20
甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%
每周股票复盘：甘李药业（603087）解聘财务负责人孙程
证券之星 · 01-02
每周股票复盘：甘李药业（603087）解聘财务负责人孙程
甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%
证券之星 · 2025-12-31
甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
长城国瑞证券：首次覆盖甘李药业给予买入评级
证券之星 · 2025-12-12
长城国瑞证券：首次覆盖甘李药业给予买入评级
全国药品流通市场销售规模略有增长；大宗中药材降价
21世纪经济报道 · 2025-12-09
全国药品流通市场销售规模略有增长；大宗中药材降价
甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书
证券之星 · 2025-12-08
甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书
甘李药业启动首个中国月药的三期临床研究（Gradual-3）
美股速递 · 2025-11-27
甘李药业启动首个中国月药的三期临床研究（Gradual-3）
甘李药业：公司业务处于正常经营状态
证券日报网 · 2025-11-26
甘李药业：公司业务处于正常经营状态
每周股票复盘：甘李药业（603087）取消监事会并修订章程
证券之星 · 2025-11-23
每周股票复盘：甘李药业（603087）取消监事会并修订章程
甘李药业（603087）披露关于董事辞任暨选举职工代表董事的公告，11月17日股价下跌2.38%
证券之星 · 2025-11-17
甘李药业（603087）披露关于董事辞任暨选举职工代表董事的公告，11月17日股价下跌2.38%
每周股票复盘：甘李药业（603087）获欧盟CHMP积极意见
证券之星 · 2025-11-16
每周股票复盘：甘李药业（603087）获欧盟CHMP积极意见
甘李药业（603087）披露拟取消监事会并修订公司章程，11月13日股价上涨0.56%
证券之星 · 2025-11-13
甘李药业（603087）披露拟取消监事会并修订公司章程，11月13日股价上涨0.56%
甘李药业(603087.SH)：甘精胰岛素注射液(Ondibta®)上市许可申请(MAA)获得欧盟CHMP积极意见
智通财经 · 2025-11-13
甘李药业(603087.SH)：甘精胰岛素注射液(Ondibta®)上市许可申请(MAA)获得欧盟CHMP积极意见
甘李药业（603087）披露新增关联方及日常关联交易预计公告，11月10日股价上涨0.84%
证券之星 · 2025-11-10
甘李药业（603087）披露新增关联方及日常关联交易预计公告，11月10日股价上涨0.84%
每周股票复盘：甘李药业（603087）股东户数增22.53%，净利升61.32%
证券之星 · 2025-11-02
每周股票复盘：甘李药业（603087）股东户数增22.53%，净利升61.32%
甘李药业(603087)9月30日股东户数9.47万户，较上期增加22.53%
证券之星 · 2025-10-31
甘李药业(603087)9月30日股东户数9.47万户，较上期增加22.53%
国金证券：给予甘李药业买入评级
证券之星 · 2025-10-31
国金证券：给予甘李药业买入评级
图解甘李药业三季报：第三季度单季净利润同比增长3.02%
证券之星 · 2025-10-30
图解甘李药业三季报：第三季度单季净利润同比增长3.02%
甘李药业（603087）披露召开2025年第三季度业绩说明会的公告，10月24日股价上涨0.73%
证券之星 · 2025-10-24
甘李药业（603087）披露召开2025年第三季度业绩说明会的公告，10月24日股价上涨0.73%
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":70.1,"timestamp":1768287601000,"preClose":69.88,"halted":0,"volume":11386201,"delay":0,"changeRate":0.0031,"floatShares":558000000,"shares":597000000,"eps":1.5499,"marketStatus":"已收盘","change":0.22,"latestTime":"01-13 15:00:00","open":69.72,"high":71.83,"low":69.7,"amount":806000000,"amplitude":0.0305,"askPrice":70.1,"askSize":172,"bidPrice":70.09,"bidSize":2,"shortable":0,"etf":0,"ttmEps":1.5499,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":69.88,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":76.87,"lowLimit":62.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597304969,"isCdr":false,"pbRate":3.71,"roa":"--","peRate":45.228724,"roe":"7.21%","epsLYR":1.04,"committee":-0.689531,"marketValue":41871000000,"turnoverRate":0.0204,"status":0,"floatMarketCap":39106000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2603468023","title":"甘李药业（603087）披露使用闲置募集资金进行现金管理进展，1月13日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603468023","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603468023?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:20","pubTimestamp":1768314033,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，甘李药业报收于70.1元，较前一交易日上涨0.31%，最新总市值为418.71亿元。该股当日开盘69.72元，最高71.83元，最低69.7元，成交额达8.06亿元，换手率为2.04%。公司近日发布公告称，甘李药业股份有限公司使用闲置募集资金25,000万元购买中国银行北京通州分行的人民币结构性存款，产品期限181天，收益类型为保本浮动收益型，预计年化收益率0.4%或2.2%，资金来源为暂时闲置的募集资金。此前到期的20,000万元结构性存款已赎回，获得收益211.25万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2600843035","title":"每周股票复盘：甘李药业（603087）解聘财务负责人孙程","url":"https://stock-news.laohu8.com/highlight/detail?id=2600843035","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600843035?lang=zh_cn&edition=full","pubTime":"2026-01-02 01:21","pubTimestamp":1767288068,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，甘李药业报收于68.29元，较上周的67.88元上涨0.6%。本周，甘李药业12月26日盘中最高价报68.5元。公司公告汇总甘李药业股份有限公司因业务调整，解聘孙程的财务负责人、副总经理职务，其不再担任公司任何职务。孙程持有已解除限售的限制性股票18.22万股，已获授但未解除限售的32.8万股将由公司回购注销。同时，会议审议通过指定周丽女士在董事会正式聘任财务负责人之前代行财务负责人职责的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2595772227","title":"甘李药业（603087）公司公告解聘高级管理人员及指定人员代行财务负责人职责，12月31日股价上涨1.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772227","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595772227?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:04","pubTimestamp":1767189861,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，甘李药业报收于68.07元，较前一交易日上涨1.66%，最新总市值为406.59亿元。近日，甘李药业发布公告称，因业务调整，公司解聘孙程的财务负责人、副总经理职务，其离职后不再担任公司任何职务。公告显示，孙程持有已解除限售的限制性股票18.22万股，已获授但未解除限售的32.8万股将由公司回购注销。为保障财务工作平稳运行，董事会指定周丽在董事会正式聘任新的财务负责人之前代行财务负责人职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09995","03692","LU2097828474.EUR","688336","LU2097828805.USD","LU0502904849.HKD","BK0057","LU1064131003.USD","LU1328615791.USD","002755","LU2488822045.USD","LU2148510915.USD","BK1161","02142","02096","LU2097828557.USD","LU1781817850.SGD","LU0405327148.USD","LU1146622755.USD","LU0405327494.USD","02509","600276","BK0196","LU2580892862.HKD","01801","LU1997245094.SGD","BK1593","688062","BK0239","BK0060","BK1589","LU1969619763.USD","LU2097828714.EUR","LU1064130708.USD","LU1997245177.USD","BK0188","LU2097828631.EUR","01167","BK0183","LU1997244956.HKD","603087","000661","BK1574","688331","01530","BK0012","06978","LU2495084118.USD","BK0028","688428"],"gpt_icon":0},{"id":"2590503214","title":"长城国瑞证券：首次覆盖甘李药业给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590503214?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:38","pubTimestamp":1765539494,"startTime":"0","endTime":"0","summary":"长城国瑞证券胡晨曦近期对甘李药业进行研究并发布了研究报告《两轮集采实现蜕变，创新+国际化驱动第二增长曲线》，首次覆盖甘李药业给予买入评级。两轮胰岛素集采中，甘李药业实现从降价换量到量价齐升的转变。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200034706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","603087"],"gpt_icon":0},{"id":"2590362722","title":"全国药品流通市场销售规模略有增长；大宗中药材降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2590362722","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590362722?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:16","pubTimestamp":1765239401,"startTime":"0","endTime":"0","summary":"政策动向全国药品流通市场销售规模略有增长12月8日，商务部发布《2024年药品流通行业运行统计分析报告》（以下简称《报告》），发布了2024年我国药品流通行业规模、行业效益、医药物流配送、医药电商、上市公司等数据，分析了行业运行特点，并对未来发展趋势进行了展望。《报告》显示，2024年，全国药品流通市场销售规模略有增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512093585873562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512093585873562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600222","BK0188","603087","BK0239"],"gpt_icon":0},{"id":"2589343333","title":"甘李药业最新公告：子公司收到GLR1044注射液药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2589343333","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589343333?lang=zh_cn&edition=full","pubTime":"2025-12-08 18:40","pubTimestamp":1765190441,"startTime":"0","endTime":"0","summary":"甘李药业(603087.SH)公告称，公司全资子公司甘李药业山东有限公司收到国家药品监督管理局下发的关于在研药品GLR1044注射液的《药物临床试验批准通知书》。GLR1044注射液为达必妥（度普利尤单抗）的生物类似药，用于治疗外用处方药控制不佳或不建议使用外用处方药的成人中重度特应性皮炎。截至2025年9月30日，甘李药业在GLR1044项目中累计投入研发费用6572.45万元人民币。由于医药产品研发周期长、环节多，存在不确定性，敬请广大投资者谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800024577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"1164568379","title":"甘李药业启动首个中国月药的三期临床研究（Gradual-3）","url":"https://stock-news.laohu8.com/highlight/detail?id=1164568379","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164568379?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:51","pubTimestamp":1764233469,"startTime":"0","endTime":"0","summary":"甘李药业启动了首个中国月药的三期临床研究（Gradual-3），旨在针对体重管理进行研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2586265391","title":"甘李药业：公司业务处于正常经营状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2586265391","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586265391?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:38","pubTimestamp":1764164280,"startTime":"0","endTime":"0","summary":"证券日报网讯甘李药业11月26日在互动平台回答投资者提问时表示，公司业务处于正常经营状态，2025年前三季度，营业收入为30.47亿元，比上年同期增加8.02亿元，同比增长35.73%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-26/doc-infytyxa9017115.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-26/doc-infytyxa9017115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2585108426","title":"每周股票复盘：甘李药业（603087）取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2585108426","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585108426?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:35","pubTimestamp":1763832910,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，甘李药业报收于60.62元，较上周的67.25元下跌9.86%。本周关注点公司公告汇总：甘李药业召开2025年第一次临时股东大会，审议通过取消监事会、修订公司章程等议案。甘李药业董事会于2025年11月17日收到非独立董事徐福明的辞职报告，因公司治理结构调整，其申请辞去第五届董事会非独立董事职务，辞职自送达董事会之日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2584621534","title":"甘李药业（603087）披露关于董事辞任暨选举职工代表董事的公告，11月17日股价下跌2.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584621534","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584621534?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:13","pubTimestamp":1763388784,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，甘李药业报收于65.65元，较前一交易日下跌2.38%，最新总市值为392.13亿元。近日，甘李药业发布公告称，公司董事会于2025年11月17日收到非独立董事徐福明先生的辞职报告，因其公司治理结构调整，申请辞去第五届董事会非独立董事职务，辞职自送达董事会之日起生效。同日，公司召开职工代表大会，选举徐福明先生为第五届董事会职工代表董事，任期至本届董事会任期届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700036569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2583656401","title":"每周股票复盘：甘李药业（603087）获欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656401","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583656401?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:29","pubTimestamp":1763227750,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，甘李药业报收于67.25元，较上周的64.06元上涨4.98%。本周，甘李药业11月14日盘中最高价报68.4元。本周关注点公司公告汇总：甘李药业甘精胰岛素注射液获欧盟CHMP积极意见，建议批准上市。甘李药业及其欧洲全资子公司收到欧洲药品管理局通知，甘精胰岛素注射液获得CHMP积极意见，建议欧盟委员会批准其作为Lantus SoloStar的生物类似药上市，用于治疗成人、青少年和2岁及以上儿童的糖尿病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FESXmain","FSXEmain","BK0239","603087"],"gpt_icon":0},{"id":"2583568924","title":"甘李药业（603087）披露拟取消监事会并修订公司章程，11月13日股价上涨0.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583568924?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:32","pubTimestamp":1763026341,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，甘李药业报收于65.93元，较前一交易日上涨0.56%，最新总市值为393.8亿元。该股当日开盘65.54元，最高65.94元，最低64.7元，成交额达5.56亿元，换手率为1.52%。根据公司于近日发布的《2025年第一次临时股东大会会议资料》，甘李药业拟取消监事会，修订《公司章程》，并办理工商变更登记。因股份回购注销，公司注册资本由601,065,290元调整为597,304,969元，股份总数相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300030333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2583550301","title":"甘李药业(603087.SH)：甘精胰岛素注射液(Ondibta®)上市许可申请(MAA)获得欧盟CHMP积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550301","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583550301?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:17","pubTimestamp":1763025442,"startTime":"0","endTime":"0","summary":"CHMP 建议欧盟委员会批准甘精胰岛素注射液作为 Lantus SoloStar 的生物类似药上市，用于治疗成人、青少年和2岁及以上儿童的糖尿病。CHMP的建议将进入EC审查阶段，以获得Ondibta在欧盟、冰岛、列支敦士登和挪威的上市许可，最终决定预计将于明年初做出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK0239","MAA","BK4087","BK4585","FESXmain","CHMP","BK4215","FSXEmain","603087"],"gpt_icon":0},{"id":"2582877861","title":"甘李药业（603087）披露新增关联方及日常关联交易预计公告，11月10日股价上涨0.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582877861?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:17","pubTimestamp":1762784271,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，甘李药业报收于64.6元，较前一交易日上涨0.84%，最新总市值为385.86亿元。近日，甘李药业发布关于新增关联方、新增2025年度及2026年度日常关联交易预计的公告。自第一步股权转让完成后，公司新增2025年度及2026年度日常关联交易预计金额合计42,820万元，其中向关联方购买商品预计41,600万元，提供服务预计1,220万元。关联交易遵循公平公允原则，不影响公司独立性，不会对关联方形成较大依赖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"gpt_icon":0},{"id":"2580478779","title":"每周股票复盘：甘李药业（603087）股东户数增22.53%，净利升61.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478779","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478779?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:47","pubTimestamp":1762019229,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，甘李药业报收于67.98元，较上周的68.83元下跌1.23%。本周，甘李药业10月28日盘中最高价报72.17元。股本股东变化股东户数变动截至2025年9月30日，甘李药业股东户数为9.47万户，较6月30日增加1.74万户，增幅22.53%。户均持股数量由7776.0股降至6309.0股，户均持股市值为47.88万元。业绩披露要点财务报告2025年前三季度，甘李药业主营收入30.47亿元，同比上升35.73%；归母净利润8.18亿元，同比上升61.32%；扣非净利润6.92亿元，同比上升122.83%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000192.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2579063459","title":"甘李药业(603087)9月30日股东户数9.47万户，较上期增加22.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579063459","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579063459?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:28","pubTimestamp":1761902887,"startTime":"0","endTime":"0","summary":"证券之星消息，近日甘李药业披露，截至2025年9月30日公司股东户数为9.47万户，较6月30日增加1.74万户，增幅为22.53%。在生物制品行业个股中，甘李药业股东户数高于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.44万户。从股价来看，2025年6月30日至2025年9月30日，甘李药业区间涨幅为38.55%，在此期间股东户数增加1.74万户，增幅为22.53%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100036408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0},{"id":"2579389444","title":"国金证券：给予甘李药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2579389444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579389444?lang=zh_cn&edition=full","pubTime":"2025-10-31 12:42","pubTimestamp":1761885736,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,马居东近期对甘李药业进行研究并发布了研究报告《制剂业务维持高增，国际化进程稳步推进》，给予甘李药业买入评级。 国际化进程稳步推进，巴西市场取得突破性进展。2025年前三季度公司实现国际销售收入为3.53亿元，同比增长45.52%。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级6家，增持评级1家；过去90天内机构目标均价为79.36。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100025873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"gpt_icon":0},{"id":"2579443701","title":"图解甘李药业三季报：第三季度单季净利润同比增长3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579443701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579443701?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:40","pubTimestamp":1761828012,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业2025年三季报显示，前三季度公司主营收入30.47亿元，同比上升35.73%；归母净利润8.18亿元，同比上升61.32%；扣非净利润6.92亿元，同比上升122.83%；其中2025年第三季度，公司单季度主营收入9.8亿元，同比上升5.39%；单季度归母净利润2.15亿元，同比上升3.02%；单季度扣非净利润2.05亿元，同比上升11.25%；负债率7.09%，投资收益1082.39万元，财务费用-6153.17万元，毛利率76.18%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"gpt_icon":0},{"id":"2577510989","title":"甘李药业（603087）披露召开2025年第三季度业绩说明会的公告，10月24日股价上涨0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577510989","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577510989?lang=zh_cn&edition=full","pubTime":"2025-10-24 22:36","pubTimestamp":1761316586,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，甘李药业报收于68.83元，较前一交易日上涨0.73%，最新总市值为411.13亿元。该股当日开盘68.36元，最高69.35元，最低68.2元，成交额达5.12亿元，换手率为1.34%。近日，甘李药业发布公告称，公司将于2025年11月3日（星期一）9:00-10:00通过上海证券交易所上证路演中心以网络互动方式召开2025年第三季度业绩说明会，就公司经营成果及财务指标与投资者进行交流。公司将于2025年10月31日在上交所网站披露《2025年第三季度报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400043047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768335410309,"stockEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0576},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.1954},{"period":"1year","weight":0.712},{"period":"ytd","weight":0.0298}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"94714人(较上一季度增加22.53%)","perCapita":"5889股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59730万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是生物制品(原料药及制剂产品)、化药、医疗器械及其他、特许权服务。2025年5月，公司被纳入标普全球《可持续发展年鉴（中国版）2025》，同时被授予“行业最佳进步企业”的荣誉称号。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}